For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

8307298296888293708280408278538232638224208220798210278198540f90edfe-fa63-4f46-b794-d091df1f36928b81c621-d7c7-4874-8776-857244600bae5f5c21f3-bf8a-4343-9092-946a33154c32fd32a9b7-2d24-441e-90cd-19ae32f64966824efe2e-5562-4126-8c4a-70cb50f5424f26ffebf4-e819-4895-871b-9da9b95c581280e5f7dc-93a3-4b2c-8e4f-a382b1980df2fa0ccf27-165d-4d27-804c-06f4c7c8d8738032d520-df4a-4af0-ab06-f895478374dd6624d335-b330-4b96-8150-bd464267202bARGS_News_2015_5_20_General_Releases.pdfARGS_News_2015_5_14_General_Releases.pdfARGS_News_2015_5_13_General_Releases.pdfARGS_News_2015_5_8_General_Releases.pdfARGS_News_2015_5_7_General_Releases.pdfARGS_News_2015_4_23_General_Releases.pdfARGS_News_2015_4_21_General_Releases.pdfARGS_News_2015_4_20_General_Releases.pdfARGS_News_2015_4_14_General_Releases.pdfARGS_News_2015_4_7_General_Releases.pdf1798326880183021754586501742120150168733143814357123456789102015-5-20T8:30:0-4:02015-5-14T16:5:0-4:02015-5-13T17:0:0-4:02015-5-8T9:44:0-4:02015-5-7T0:0:0-4:02015-4-23T10:15:0-4:02015-4-21T8:30:0-4:02015-4-20T8:30:0-4:02015-4-14T8:0:0-4:02015-4-7T16:30:0-4:0914099913314913033912025911893908278907629907340906406905314General ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesPresentations to Highlight Advantages of the Arcelis(R) Technology Platform for Developing and Commercializing Fully Personalized Immunotherapies<p><i>-Interim Data Analyses from the Phase 3 ADAPT Trial At Approximately 25% of Events Expected During ASCO Annual Meeting-</i></p><p><i>- Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET -</i></p>Update to be Presented in Poster Session at American Society of Clinical Oncology Annual Meeting, Positions Trial for Full Enrollment by End of June 2015Insights on Leukapheresis Collection From Pivotal ADAPT Phase 3 Clinical Trial to be PresentedDeveloper of Fully Personalized Immunotherapies Recently Broke Ground on 100,000 Square Foot Manufacturing Facility With Plans to Create Nearly 250 New Jobs in DurhamEncouraging Survival With the Combination of AGS-003 Plus Sunitinib in Unfavorable Risk mRCC Published in Journal for ImmunoTherapy of CancerFully Personalized Immunotherapy Based on the Arcelis(R) Technology Platform is Being Evaluated for the Treatment of Metastatic Renal Cell Carcinoma.Lummy HK Obtains Rights to Manufacture, Develop and Commercialize AGS-003 in China, Hong Kong, Taiwan, and MacauArgos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational HighlightsArgos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical TrialArgos Therapeutics to Present at 36th American Society for Apheresis Annual MeetingArgos Therapeutics to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion AwardsArgos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual MeetingArgos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in ChinaArgos Therapeutics to Present at the 14th Annual Needham Healthcare Conference999999999999999999992015201520152015201520152015201520152015No Error0

Argos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015
Read more

Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial
Read more

Argos Therapeutics to Present at 36th American Society for Apheresis Annual Meeting
Read more

Argos Therapeutics to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015
Read more

Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion Awards
Read more

Argos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)
Read more

Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting
Read more

Argos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in China
Read more

Argos Therapeutics to Present at the 14th Annual Needham Healthcare Conference
Read more